CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice

Journal of Lipid Research

Volumn 51, Issue 1, 2010, Pages 97-102

  Bijland, Silvia ^a   van den Berg, Sjoerd A A ^a   Voshol, Peter J ^a   van den Hoek, Anita M ^b   Princen, Hans M G ^b   Havekes, Loius M ^a,b   Rensen, Patrick C N ^a   van Dijk, Ko Willems ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Cholesteryl ester transfer protein; HDL; Postprandial lipoproteins; Triglyceride metabolism

Indexed keywords

APOLIPOPROTEIN E3; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; LIPID TRANSPORT; LIPOGENESIS; MALE; METABOLIC CLEARANCE RATE; MOUSE; NONHUMAN; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; TISSUE SPECIFICITY;

ANIMALS; APOLIPOPROTEIN E3; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, VLDL; DIETARY FATS; FEMALE; HUMANS; LIPID METABOLISM; MALE; MICE; MICE, TRANSGENIC; OBESITY; TRANSGENES; TRIGLYCERIDES;

EID: 73149107751     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M900186-JLR200     Document Type: Article

References (29)

1. Boden, W. E. 2000. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am. J. Cardiol. 86: 19L-22L.
2. Nordestgaard, B. G., M. Benn, P. Schnohr, and A. Tybjaerg-Hansen. 2007. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 298: 299-308.
3. Westerterp, M., C. C. van der Hoogt, W. de Haan, E. H. Offerman, G. M. Dallinga-Thie, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2006. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler. Thromb. Vasc. Biol. 26: 2552-2559.
4. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122.
5. Bloomfield, D., G. L. Carlson, A. Sapre, D. Tribble, J. M. McKenney, T. W. Littlejohn III, C. M. Sisk, Y. Mitchel, and R. C. Pasternak. 2009. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 157: 352-360.
6. Rennings, A. J., and A. F. Stalenhoef. 2008. JTT-705: is there still future for a CETP inhibitor after torcetrapib? Expert Opin. Investig. Drugs. 17: 1589-1597.
7. Clark, R. W., T. A. Sutfin, R. B. Ruggeri, A. T. Willauer, E. D. Sugarman, G. Magnus-Aryitey, P. G. Cosgrove, T. M. Sand, R. T. Wester, J. A. Williams, et al. 2004. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24: 490-497.
8. de Grooth, G. J., J. A. Kuivenhoven, A. F. Stalenhoef, J. de Graaf, A. H. Zwinderman, J. L. Posma, A. van Tol, and J. J. Kastelein. 2002. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105: 2159-2165.
9. Hermann, F., F. Enseleit, L. E. Spieker, D. Periat, I. Sudano, M. Hermann, R. Corti, G. Noll, F. Ruschitzka, and T. F. Luscher. 2009. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thromb. Res. 123: 460-465.
10. Rashid, S., D. K. Trinh, K. D. Uffelman, J. S. Cohn, D. J. Rader, and G. F. Lewis. 2003. Expression of human hepatic lipase in the rabbit model preferentially enhances the clearance of triglyceride-enriched versus native high-density lipoprotein apolipoprotein A-I. Circulation. 107: 3066-3072.
11. Jiang, X. C., L. B. Agellon, A. Walsh, J. L. Breslow, and A. Tall. 1992. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J. Clin. Invest. 90: 1290-1295.
12. van den Maagdenberg, A. M., M. H. Hofker, P. J. Krimpenfort, I. de Bruijn, B. van Vlijmen, H. van der Boom, L. M. Havekes, and R. R. Frants. 1993. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J. Biol. Chem. 268: 10540-10545.
13. Berbee, J. F., C. C. van der Hoogt, D. Sundararaman, L. M. Havekes, and P. C. Rensen. 2005. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J. Lipid Res. 46: 297-306.
14. Aalto-Setala, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90: 1889-1900.
15. Pietzsch, J., S. Subat, S. Nitzsche, W. Leonhardt, K. U. Schentke, and M. Hanefeld. 1995. Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim. Biophys. Acta. 1254: 77-88.
16. Li, X., F. Catalina, S. M. Grundy, and S. Patel. 1996. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. J. Lipid Res. 37: 210-220.
17. Egusa, G., D. W. Brady, S. M. Grundy, and B. V. Howard. 1983. Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. J. Lipid Res. 24: 1261-1267.
18. Rensen, P. C., N. Herijgers, M. H. Netscher, S. C. Meskers, M. van Eck, and T. J. van Berkel. 1997. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J. Lipid Res. 38: 1070-1084.
19. Teusink, B., P. J. Voshol, V. E. Dahlmans, P. C. Rensen, H. Pijl, J. A. Romijn, and L. M. Havekes. 2003. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes. 52: 614-620.
20. de Vries-van der Weij, J., W. de Haan, L. Hu, M. Kuif, H. L. Oei, J. W. van der Hoorn, L. M. Havekes, H. M. Princen, J. A. Romijn, J. W. Smit, et al. 2009. Bexarotene induces dyslipidemia by increased VLDL production and cholesteryl ester transfer protein (CETP)-mediated reduction of HDL. Endocrinology. 150: 2368-2375.
21. Rensen, P. C., M. C. Jong, L. C. van Vark, H. van der Boom, W. L. Hendriks, T. J. van Berkel, E. A. Biessen, and L. M. Havekes. 2000. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J. Biol. Chem. 275: 8564-8571.
22. Voshol, P. J., P. C. Rensen, K. W. van Dijk, J. A. Romijn, and L. M. Havekes. 2009. Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: studies using genetically engineered mouse models. Biochim. Biophys. Acta. 1791: 479-485.
23. Zadelaar, S., R. Kleemann, L. Verschuren, J. de Vries-van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra. 2007. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 27: 1706-1721.
24. Escola-Gil, J. C., J. Julve, A. Marzal-Casacuberta, J. Ordonez-Llanos, F. Gonzalez-Sastre, and F. Blanco-Vaca. 2001. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. J. Lipid Res. 42: 241-248.
25. Salerno, A. G., P. R. Patricio, J. A. Berti, and H. C. Oliveira. 2009. Cholesteryl ester transfer protein (CETP) increases postprandial triglyceridemia and delays triglyceride plasma clearance in transgenic mice. Biochem. J. 419: 629-634.
26. Harada, L. M., L. Amigo, P. M. Cazita, A. G. Salerno, A. A. Rigotti, E. C. Quintao, and H. C. Oliveira. 2007. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis. 191: 313-318.
27. Lamarche, B., K. D. Uffelman, A. Carpentier, J. S. Cohn, G. Steiner, P. H. Barrett, and G. F. Lewis. 1999. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J. Clin. Invest. 103: 1191-1199.
28. Melchior, G. W., C. K. Castle, R. W. Murray, W. L. Blake, D. M. Dinh, and K. R. Marotti. 1994. Apolipoprotein A-I metabolism in cholesteryl ester transfer protein transgenic mice. Insights into the mechanisms responsible for low plasma high density lipoprotein levels. J. Biol. Chem. 269: 8044-8051.
29. Rashid, S., P. H. Barrett, K. D. Uffelman, T. Watanabe, K. Adeli, and G. F. Lewis. 2002. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler. Thromb. Vasc. Biol. 22: 483-487.